The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 18, 2020
Filed:
Sep. 13, 2017
Applicant:
National Taiwan University, Taipei, TW;
Inventors:
Jang-Ming Lee, Taipei, TW;
I-Jen Hsu, Taipei, TW;
Max Ti-Kuang Hou, Taipei, TW;
Pei-Wen Yang, Taipei, TW;
Assignee:
NATIONAL TAIWAN UNIVERSITY, Taipei, TW;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/48 (2006.01); G01N 21/31 (2006.01); G06F 19/00 (2018.01); G01N 33/574 (2006.01); G16H 20/40 (2018.01); G16H 50/30 (2018.01); G16H 20/10 (2018.01); G16H 50/70 (2018.01); G06G 7/58 (2006.01); G01N 21/17 (2006.01);
U.S. Cl.
CPC ...
G01N 21/31 (2013.01); G01N 33/574 (2013.01); G06F 19/34 (2013.01); G16H 20/10 (2018.01); G16H 20/40 (2018.01); G16H 50/30 (2018.01); G16H 50/70 (2018.01); G01N 2021/1742 (2013.01); G01N 2201/1293 (2013.01); G01N 2800/52 (2013.01);
Abstract
The present invention provides an optical method for predicting treatment response, survival and recurrence of esophageal cancer patients, comprising analyzing the spectral signatures of patient's tumor tissue spectra. By the features of the present invention, the prediction result achieves the sensitivity of 75% and specificity of 73.3% in concurrent chemoradiotherapy (CCRT) response; the survival prediction rate achieves the sensitivity of 100%; the recurrence prediction rate achieves the sensitivity of 85.7%.